Evaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic?

Basit Öğe Kaydı
dc.contributor.authorArslan, Eyup
dc.contributor.authorYildiz, Yesim
dc.contributor.authorKarasahin, Omer
dc.contributor.authorDemir, Yakup
dc.contributor.authorMermutluoglu, Cigdem Tumbul
dc.contributor.authorUnlu, Gulten
dc.contributor.authorKuscu, Ferit
dc.date.accessioned2024-04-24T17:08:21Z
dc.date.available2024-04-24T17:08:21Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectiveThe uncertain treatment duration for nucleos(t)ide analogues (NA) used in the treatment of chronic hepatitis B (CHB) is an important problem for both patients and physicians. The aim of this study was to evaluate the determinants of virologic relapse (VR) and the optimum time of treatment discontinuation in the follow-up of CHB patients who voluntarily discontinued treatment after virological suppression was achieved under NA use.MethodsData from 138 patients from 11 centers were included in this registry-based study. Factors associated with VR were investigated using multivariate Cox regression analysis.ResultsNinety-nine (71.7%) of the patients were HBeAg (Hepatitis B e antigen) negative. During the 24-month follow-up period after treatment discontinuation, VR occurred in 58.7% (n = 81) of all patients and 57.6% (n = 57) of HBeAg-negative patients. The duration of NA treatment was significantly shorter (cutoff 60 months) in HBeAg-negative patients who later developed VR. In addition, the duration of virologic remission achieved under NA treatment was significantly shorter (cutoff 52 months) in those who later developed VR. In the Cox multivariate regression model of HBeAg-negative patients, having less than 60 months of NA treatment (HR = 2.568; CI:1.280-5.148; P = 0.008) and the levels of alanine aminotransferase being equal to or higher than twice the upper level of normal at the beginning of treatment (HR = 3.753; CI:1.551-9.081; P = 0.003) were found to be statistically significant and independently associated with VR.ConclusionThe findings of this study may provide clinical guidance in terms of determining the most appropriate discontinuation time for NA.en_US
dc.identifier.doi10.1097/MEG.0000000000002722
dc.identifier.endpage444en_US
dc.identifier.issn0954-691X
dc.identifier.issn1473-5687
dc.identifier.issue4en_US
dc.identifier.pmid38407855
dc.identifier.scopus2-s2.0-85186491955
dc.identifier.scopusqualityQ2
dc.identifier.startpage438en_US
dc.identifier.urihttps://doi.org/10.1097/MEG.0000000000002722
dc.identifier.urihttps://hdl.handle.net/11468/17313
dc.identifier.volume36en_US
dc.identifier.wosWOS:001183671900008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofEuropean Journal of Gastroenterology & Hepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis Ben_US
dc.subjectNucleos(T)Ide Analogueen_US
dc.subjectTreatment Discontinuationen_US
dc.subjectTreatment Durationen_US
dc.subjectVirologic Relapseen_US
dc.titleEvaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic?en_US
dc.titleEvaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu